SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Carter, T. L. Articles by Kees, U. R. Search for Related Content PubMed PubMed Citation Articles by Carter, T. L. Articles by Kees, U. R. Related Collections Neoplasia Oncogenes and Tumor Suppressors Brief Reports Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 January 2001, Vol. 97, No. 2, pp. 572-574 BRIEF REPORT Hemizygous p16INK4A deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse Tina L. Carter, Paul M. Watt, Rolee Kumar, Paul R. Burton, Gregory H. Reaman, Harland N. Sather, David L. Baker, and Ursula R. Kees From the Division of Children's Leukaemia and Cancer Research and the Division of Biostatistics and Genetic Epidemiology, TVWT Institute for Child Health Research, Centre for Child Health Research, Faculty of Medicine and Dentistry, University of Western Australia; the Department of Haematology-Oncology, Princess Margaret Hospital, Perth, Australia; the Children's National Medical Center, The George Washington University, Washington, DC; the Children's Cancer Group, Arcadia, CA; and the Genetic Epidemiology Unit, Department of Epidemiology and Public Health, University of Leicester, Leicester, United Kingdom. The genes at the INK4A/ARF locus at 9p21 are frequently involved in human cancer. Virtually all p16INK4A exon 2 (henceforth called p16) inactivation in pediatric acute lymphoblastic leukemia (ALL) occurs by gene deletion. The results of this study illustrate that real-time quantitative polymerase chain reaction is capable of detecting gene deletion in primary patient specimens with a precision not previously achieved by conventional methods. Importantly, this assay includes the detection of hemizygous deletions. The study revealed, strikingly, that the risk ratio for relapse for hemizygous deletion compared with no deletion was 6.558 (P = .00687) and for homozygous deletion was 11.558 (P = .000539). These results confirm and extend the authors' previous findings that homozygous deletion of p16 in pediatric ALL patients is an independent prognostic indicator of outcome from therapy. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Prognostic value of p16INK4a gene deletions in pediatric acute lymphoblastic leukemia Hagen Graf Einsiedel, Tillmann Taube, Reinhard Hartmann, Cornelia Eckert, Georg Seifert, Sven Wellmann, Günter Henze, Karl Seeger, Ursula R. Kees, Tina L. Carter, Paul M. Watt, Rolee Kumar, David L. Baker, Gregory H. Reaman, Harland N. Sather, and Paul R. Burton Blood 2001 97: 4002-4004. [Full Text] [PDF] This article has been cited by other articles: S. Sulong, A. V. Moorman, J. A. E. Irving, J. C. Strefford, Z. J. Konn, M. C. Case, L. Minto, K. E. Barber, H. Parker, S. L. Wright, et al. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups Blood, January 1, 2009; 113(1): 100 - 107. [Abstract] [Full Text] [PDF] E. J. Chapman, P. Harnden, P. Chambers, C. Johnston, and M. A. Knowles Comprehensive Analysis of CDKN2A Status in Microdissected Urothelial Cell Carcinoma Reveals Potential Haploinsufficiency, a High Frequency of Homozygous Co-deletion and Associations with Clinical Phenotype Clin. Cancer Res., August 15, 2005; 11(16): 5740 - 5747. [Abstract] [Full Text] [PDF] Section on Hematology/Oncology Guidelines for Pediatric Cancer Centers Pediatrics, June 1, 2004; 113(6): 1833 - 1835. [Abstract] [Full Text] [PDF] J. Li, C. M. Weghorst, M. Tsutsumi, M. J. Poi, T. J. Knobloch, B. C. Casto, W. S. Melvin, M.-D. Tsai, and P. Muscarella Frequent p16INK4A/CDKN2A alterations in chemically induced Syrian golden hamster pancreatic tumors Carcinogenesis, February 1, 2004; 25(2): 263 - 268. [Abstract] [Full Text] [PDF] F. Tort, S. Hernandez, S. Bea, A. Martinez, M. Esteller, J. G. Herman, X. Puig, E. Camacho, M. Sanchez, I. Nayach, et al. CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas Blood, December 15, 2002; 100(13): 4602 - 4608. [Abstract] [Full Text] [PDF] P. Ballerini, A. Blaise, M. Busson-Le Coniat, X. Y. Su, J. Zucman-Rossi, M. Adam, J. van den Akker, C. Perot, B. Pellegrino, J. Landman-Parker, et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis Blood, July 18, 2002; 100(3): 991 - 997. [Abstract] [Full Text] [PDF] H. Graf Einsiedel, T. Taube, R. Hartmann, S. Wellmann, G. Seifert, G. Henze, and K. Seeger Deletion analysis of p16INKa and p15INKb in relapsed childhood acute lymphoblastic leukemia Blood, May 29, 2002; 99(12): 4629 - 4631. [Abstract] [Full Text] [PDF] J. H. Dalle, M. Fournier, B. Nelken, F. Mazingue, J.-L. Lai, F. Bauters, P. Fenaux, and B. Quesnel p16INK4a immunocytochemical analysis is an independent prognostic factor in childhood acute lymphoblastic leukemia Blood, April 1, 2002; 99(7): 2620 - 2623. [Abstract] [Full Text] [PDF] H. G. Einsiedel, T. Taube, R. Hartmann, C. Eckert, G. Seifert, S. Wellmann, G. Henze, K. Seeger, U. R. Kees, T. L. Carter, et al. Prognostic value of p16INK4a gene deletions in pediatric acute lymphoblastic leukemia Blood, June 15, 2001; 97(12): 4002 - 4004. [Full Text] [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020